DK1117437T3 - Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde - Google Patents

Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde

Info

Publication number
DK1117437T3
DK1117437T3 DK99948942T DK99948942T DK1117437T3 DK 1117437 T3 DK1117437 T3 DK 1117437T3 DK 99948942 T DK99948942 T DK 99948942T DK 99948942 T DK99948942 T DK 99948942T DK 1117437 T3 DK1117437 T3 DK 1117437T3
Authority
DK
Denmark
Prior art keywords
treatment
antiplasmin
ischemic stroke
vivo
compounds
Prior art date
Application number
DK99948942T
Other languages
Danish (da)
English (en)
Inventor
Desire Jose Collen
Nobuo Nagai
Original Assignee
Leuven Res & Dev Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202004A external-priority patent/EP1062953A1/en
Application filed by Leuven Res & Dev Vzw filed Critical Leuven Res & Dev Vzw
Application granted granted Critical
Publication of DK1117437T3 publication Critical patent/DK1117437T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
DK99948942T 1998-09-29 1999-09-24 Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde DK1117437T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98203280 1998-09-29
EP99202004A EP1062953A1 (en) 1999-06-22 1999-06-22 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
PCT/EP1999/007405 WO2000018436A1 (en) 1998-09-29 1999-09-24 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke

Publications (1)

Publication Number Publication Date
DK1117437T3 true DK1117437T3 (da) 2007-04-10

Family

ID=26150731

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99948942T DK1117437T3 (da) 1998-09-29 1999-09-24 Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde

Country Status (12)

Country Link
US (1) US6946438B1 (ja)
EP (1) EP1117437B1 (ja)
JP (1) JP4577992B2 (ja)
CN (1) CN1191856C (ja)
AT (1) ATE349226T1 (ja)
AU (1) AU6200599A (ja)
CA (1) CA2344317C (ja)
DE (1) DE69934595T2 (ja)
DK (1) DK1117437T3 (ja)
ES (1) ES2276536T3 (ja)
HK (1) HK1041449B (ja)
WO (1) WO2000018436A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60131450T2 (de) * 2000-12-21 2008-10-16 Thrombogenics N.V. Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle
CN1684706A (zh) * 2002-07-23 2005-10-19 路德维格癌症研究所 活化或抑制vegf－d和vegf－c的方法和组合物
EP2246417B1 (en) * 2004-04-22 2015-01-21 Grifols Therapeutics Inc. Recombinantly modified plasmin
AU2008331545B2 (en) * 2007-11-29 2014-01-16 Grifols Therapeutics Inc. Recombinantly modified plasmin
EP2297317A4 (en) * 2008-06-04 2011-12-07 Talecris Biotherapeutics Inc COMPOSITION, METHOD AND NECESSARY FOR THE PREPARATION OF PLASMINE
HUE025670T2 (en) 2009-03-03 2016-04-28 Grifols Therapeutics Inc A method for producing plasminogen
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
CA2846667A1 (en) * 2011-09-06 2013-03-14 Guy L. Reed Serpinf2-binding molecules and methods of use
EP3395355A4 (en) 2015-12-18 2019-06-12 Talengen International Limited METHOD FOR PREVENTING AND TREATING CERVICAL EROSION
CN106890325A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
WO2017101873A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
DK3391902T3 (da) 2015-12-18 2023-11-20 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
CN108463240A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
EP3556384B1 (en) 2016-12-15 2024-04-10 Talengen International Limited Plasminogen for use in treating diabetes
US20230134886A1 (en) * 2019-10-10 2023-05-04 University Of Kentucky Research Foundation A machine learning algorithm for predicting clinical outcomes and identifying drug targets in ischemic stroke
WO2023004626A1 (zh) * 2021-07-28 2023-02-02 北京沙东生物技术有限公司 一种骨髓瘤生物标志物serpinf2及其应用
CN114736948B (zh) * 2022-06-10 2022-11-08 深圳市帝迈生物技术有限公司 一种α2-抗纤溶酶活性测定试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
WO1998012329A2 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin

Also Published As

Publication number Publication date
ATE349226T1 (de) 2007-01-15
HK1041449B (zh) 2005-08-19
ES2276536T3 (es) 2007-06-16
CA2344317A1 (en) 2000-04-06
HK1041449A1 (en) 2002-07-12
WO2000018436A1 (en) 2000-04-06
EP1117437B1 (en) 2006-12-27
DE69934595D1 (de) 2007-02-08
US6946438B1 (en) 2005-09-20
CN1191856C (zh) 2005-03-09
JP2002525340A (ja) 2002-08-13
CA2344317C (en) 2012-01-24
AU6200599A (en) 2000-04-17
JP4577992B2 (ja) 2010-11-10
EP1117437A1 (en) 2001-07-25
DE69934595T2 (de) 2007-10-04
CN1320045A (zh) 2001-10-31

Similar Documents

Publication Publication Date Title
DK1117437T3 (da) Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde
YU23102A (sh) Jedinjenja za lečenje ishemije
FR2627696B1 (fr) Nouvelle forme galenique du fenofibrate
BR0215405A (pt) Composições e processos de uso de collajolie
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
TR200001203T2 (tr) Yeni birleşik maddeler
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
DE69940769D1 (de) Orale flüssige zusammensetzungen
IL153014A0 (en) Barbituric acid analogs as therapeutic agents
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
ATE368023T1 (de) Hydroxydiphenyletherverbindungen
GB0111186D0 (en) Novel compounds
BG101867A (en) Benzothiazenedioxides as endothelin antagonists
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
SE9901077D0 (sv) Novel use
DK1017684T3 (da) Kontrastmiddel til afbildning af infarkter og nekroser
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
SE9804212D0 (sv) Compounds
NO20011664L (no) Sammensetning med höy renhet omfattende (7<alfa>, 17<alfa>)- 17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина
ITRM20010136A0 (it) Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.
IT1312375B1 (it) Composizione topica per l'eliminazione di tatuaggi.